Please login to the form below

Not currently logged in
Email:
Password:

BenevolentAI appoints new head of cheminformatics

Dr Nathan Brown joins from the Institute of Cancer Research

Artificial Intelligence (AI) group BenevolentAI has appointed Dr Nathan Brown as its new head of cheminformatics.

Brown joins the group from the Institute of Cancer Research (ICR), where he founded and led the new In Silico Medicinal Chemistry Group, which focussed on medicinal chemistry research towards novel cancer treatments.

He also has experience as a software designer and has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology.

Jackie Hunter, CEO of BenevolentBio, the bioscience subsidiary of BenevolentAI, said: “Nathan is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry.

“He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published. We are delighted to have him on board.”

Brown succeeds Mark Davies who has been promoted to vice president, Biomedical Informatics.

1st August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics